ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Cancer
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will...
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
Secure Transfusion Solutions Announces Company Name Change and Opening of its Third Trusting Heart Blood Center in Beaverton, Oregon
Formerly recognized as Secure Transfusion Services, the company will now be known as “Secure Transfusion Solutions,” and has moved its...
Trusting Heart Blood Center Announces the Opening of its Third Platelet Donation Center in Beaverton, Oregon
BEAVERTON, Ore., July 20, 2022 (GLOBE NEWSWIRE) -- Trusting Heart Blood Center (THBC) announces the opening of its new platelet...
Altamira Therapeutic’s SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy
Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary...
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers
Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
Company Announcement Net sales of DARZALEX® in the second quarter of 2022 totaled USD 1,986 millionGenmab receives royalties on worldwide...
Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board
Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal)...
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew...
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Combination trial to be initiated in Q4 2022CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV...
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of...
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial...
GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians
MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
NYMOX Updates Shareholders
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders...
DTC genetics company Nucleus Genomics raises $18 million in funding in one year
Seed+ funding round led by Seven Seven Six nets $14 million New York, July 14, 2022 /PRNewswire/ -- Nucleus Genomics,...